AILERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5 USD | 0.00% |
|
+5.49% | +64.01% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 84.86M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-2.76
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aileron Therapeutics, Inc.
More recommendations
More press releases
| 1 week | +5.49% | ||
| Current month | -24.59% | ||
| 1 month | -12.28% | ||
| 3 months | -0.79% | ||
| 6 months | +309.84% | ||
| Current year | +64.01% |
1 week
4.27
5.43
1 month
4.127.42
Current year
2.877.42
1 year
1.017.42
3 years
1.0128.00
5 years
1.0149.40
10 years
1.01309.60
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
| Director of Finance/CFO | 48 | 23-09-30 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 61 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5 | 0.00% | 85,369 |
| 24-04-25 | 5 | +1.42% | 80,550 |
| 24-04-24 | 4.93 | +3.79% | 102,254 |
| 24-04-23 | 4.75 | 0.00% | 67,716 |
| 24-04-22 | 4.75 | +0.21% | 109,866 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5
USD
Average target price
19
USD
Spread / Average Target
+280.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +64.01% | 84.86M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALRN Stock
